What is the level of liabilities of Globeimmune this year?
Globeimmune has a debt balance of 0 USD this year.
Globeimmune Liabilities 2024
Globeimmune Liabilities
0 USD
Ticker
GBIM
ISIN
US37957B1008
WKN
A1J41J
In 2024, Globeimmune's total liabilities amounted to 0 USD, a 0% difference from the 0 USD total liabilities in the previous year.
Globeimmune Aktienanalyse
What does Globeimmune do?
Globeimmune Inc. is a biopharmaceutical company that focuses on the development of immunotherapies for various types of cancer. The company was founded in 1998 in Louisville, Colorado, USA, and went public in 2014. Globeimmune's business model revolves around the use of its patented Tarmogen technology, which aims to activate the immune system against cancer cells. The company has conducted clinical studies for its treatments targeting pancreatic, lung, and prostate cancer. Globeimmune has also formed partnerships with other pharmaceutical companies, including one with Sanko Junyaku in Japan to market its Tarmogen technology in Asia. The company's product range includes various immunotherapies based on the Tarmogen technology, such as GI-4000 for pancreatic cancer, GI-6207 for prostate cancer, and GI-6301 for lung cancer. Globeimmune has achieved success in recent years, including completing a financing round of $15.6 million in 2012 and going public with a $35 million IPO in 2014. Overall, Globeimmune is a promising biopharmaceutical company that focuses on developing effective immunotherapies for cancer patients using its Tarmogen technology, which has the potential to revolutionize cancer treatment and provide patients with effective and gentle therapies. Globeimmune ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Globeimmune's Liabilities
Globeimmune's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Globeimmune's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Globeimmune's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Globeimmune's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Globeimmune’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Globeimmune stock
What were the liabilities of Globeimmune compared to the previous year?
The liabilities of Globeimmune have increased by 0% dropped compared to the previous year.
What are the consequences of high debt for investors of Globeimmune?
High liabilities can pose a risk for investors of Globeimmune, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Globeimmune?
Low liabilities mean that Globeimmune has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Globeimmune affect the company?
An increase in liabilities of Globeimmune can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Globeimmune affect the company?
A decrease in the liabilities of Globeimmune can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Globeimmune?
Some factors that can influence the liabilities of Globeimmune include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Globeimmune so important for investors?
The liabilities of Globeimmune are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Globeimmune take to modify the liabilities?
To change its liabilities, Globeimmune can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Globeimmune pay?
Over the past 12 months, Globeimmune paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Globeimmune is expected to pay a dividend of 0 USD.
What is the dividend yield of Globeimmune?
The current dividend yield of Globeimmune is .
When does Globeimmune pay dividends?
Globeimmune pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Globeimmune?
Globeimmune paid dividends every year for the past 0 years.
What is the dividend of Globeimmune?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Globeimmune located?
Globeimmune is assigned to the 'Health' sector.
Wann musste ich die Aktien von Globeimmune kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Globeimmune from 10/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/25/2024.
When did Globeimmune pay the last dividend?
The last dividend was paid out on 10/25/2024.
What was the dividend of Globeimmune in the year 2023?
In the year 2023, Globeimmune distributed 0 USD as dividends.
In which currency does Globeimmune pay out the dividend?
The dividends of Globeimmune are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Globeimmune
Our stock analysis for Globeimmune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Globeimmune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
